Literature DB >> 11871319

[Evaluation of the effectiveness of antibacterial substances in treating an experimental form of bubonic plague in monkeys].

V E Romanov1, V I Evstigneev, N T Vasil'ev, B A Shabalin, V E Paramonov.   

Abstract

The modelling of glandular plague and selection of the conditions for estimating the efficacy of new antibacterials for the treatment of the infection were performed on hamadryads (baboons). The experiments showed that the average LD50 of the culture of a highly virulent strain of Yersinia pestis on its subcutaneous administration to the animals was 2089 viable microbes. In 18 per cent of the episodes the experimental glandular plague in the animals was complicated by secondary plague pneumonia. Subcutaneous administration of 2 x 10(7) viable microbial cell of the plague pathogen caused acute sepsis and the animal death. The treatment of the experimental glandular plague in the hamadryads demonstrated that new antibacterials such as amikacin, netilmicin, ceftriaxone, cefotaxime, ceftizoxime, doxycycline, rifampicin, ofloxacin and ciprofloxacin were not inferior in their efficacy to streptomycin and tetracycline successfully used in the therapy of patients with plague.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11871319

Source DB:  PubMed          Journal:  Antibiot Khimioter        ISSN: 0235-2990


  2 in total

Review 1.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

2.  An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial.

Authors:  Rindra Vatosoa Randremanana; Mihaja Raberahona; Mamy Jean de Dieu Randria; Minoarisoa Rajerison; Voahangy Andrianaivoarimanana; Agathe Legrand; Tsinjo Fehizoro Rasoanaivo; Ravaka Randriamparany; Théodora Mayouya-Gamana; Reziky Mangahasimbola; Josie Bourner; Alex Salam; Annelies Gillesen; Tansy Edwards; Matthieu Schoenhals; Laurence Baril; Peter Horby; Piero Olliaro
Journal:  Trials       Date:  2020-08-17       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.